ipilimumab intradermal / GE Healthcare - LARVOL DELTA

Neoadjuvant intradermal ipilimumab and nivolumab in high-risk stage II melanoma – MARIANE (ESMO 2026) - No abstract available

Clinical • Melanoma • Oncology • Solid Tumor

IpiD: Comparing Intravenous or Intradermal Administration of Anti-CTLA-4 in Combination With Anti-PD1 Treatment in Patients With Melanoma (clinicaltrials.gov) - P1/2 | N=18 | Not yet recruiting | Sponsor: Amsterdam UMC, location VUmc

New P1/2 trial • Cutaneous Melanoma • Genetic Disorders • Melanoma • Oncology • Skin Cancer • Solid Tumor